Acute Ethanol Dose
Phase 1
Acute Ethanol Dose is one of 7 therapeutic programs targeting GLP-1. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
6 competitors in GLP-1
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Ozempic
Novo NordiskPhase 2
Welchol
CCosette Pharmaceuticals, Inc.
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Dipeptidyl Peptidase 4 Inhibitor
Boehringer IngelheimPreclinical
Acute Ethanol Dose
UUniversity of Wisconsin, Madison
Phase 1
Chenodeoxycholic Acid
LLeadiant Biosciences, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Acute Ethanol Dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Wisconsin, Madison